ArticleInfection and immunity2004
Age-specific immunoglobulin g (IgG) and IgA to pneumococcal protein antigens in a population in coastal kenya.
Article in Infection and immunity, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- Acquisition of pneumococci specific effector and regulatory Cd4+ T cells localising within human upper respiratory-tract mucosal lymphoid tissue.PLoS pathogens · 2011Trial
- Serological Profiling of Pneumococcal Proteins Reveals Unique Patterns of Acquisition, Maintenance, and Waning of Antibodies Throughout Life.The Journal of infectious diseases · 2024Article
- Genomic and panproteomic analysis of the development of infant immune responses to antigenically-diverse pneumococci.Nature communications · 2024Article
- Article
- Identification of SP1683 as a pneumococcal protein that is protective against nasopharyngeal colonization.Human vaccines & immunotherapeutics · 2018Article
- Intranasal Vaccination With Lipoproteins Confers Protection Against Pneumococcal Colonisation.Frontiers in immunology · 2018Article
- A novel flow cytometry-based assay for the quantification of antibody-dependent pneumococcal agglutination.PloS one · 2017Article
- Natural Development of Antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Protein Antigens during the First 13 Years of Life.Clinical and vaccine immunology : CVI · 2016Article
- Rationale and prospects for novel pneumococcal vaccines.Human vaccines & immunotherapeutics · 2016Review
- A longitudinal study of natural antibody development to pneumococcal surface protein A families 1 and 2 in Papua New Guinean Highland children: a cohort study.Pneumonia (Nathan Qld.) · 2016Article
- Article
- Serum antibody responses to pneumococcal colonization in the first 2 years of life: results from an SE Asian longitudinal cohort study.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2013Article
- Serotype-independent pneumococcal vaccines.Cellular and molecular life sciences : CMLS · 2013Review
- Increased IgG but normal IgA anti-pneumococcal protein antibodies in lung of HIV-infected adults.Vaccine · 2013Article
- Maternal antibodies to pneumolysin but not to pneumococcal surface protein A delay early pneumococcal carriage in high-risk Papua New Guinean infants.Clinical and vaccine immunology : CVI · 2009Article
- Antibodies to pneumococcal proteins PhtD, CbpA, and LytC in Filipino pregnant women and their infants in relation to pneumococcal carriage.Clinical and vaccine immunology : CVI · 2009Article
- Development of antibodies to PspA families 1 and 2 in children after exposure to Streptococcus pneumoniae.Clinical and vaccine immunology : CVI · 2008Article
- Interleukin-17A mediates acquired immunity to pneumococcal colonization.PLoS pathogens · 2008Article
- Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins.Clinical and vaccine immunology : CVI · 2008Article
- Pneumonia research to reduce childhood mortality in the developing world.The Journal of clinical investigation · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
Abstract
Streptococcus pneumoniae is the primary etiological agent of community-acquired pneumonia and a major cause of meningitis and bacteremia. Three conserved pneumococcal proteins-pneumolysin, pneumococcal surface adhesin A (PsaA), and pneumococcal surface protein A (PspA)-are currently being investigated as vaccine candidates. Such protein-based vaccines, if proven effective, could provide a cheaper alternative to conjugate vaccine formulae. Few data from sub-Saharan Africa exist concerning the development of natural antibody to these antigens, however. To investigate the age-specific development of antiprotein immunoglobulin G (IgG) and IgA antibody responses, the sera of 220 persons 2 weeks to 84 years of age from coastal Kenya were assayed using enzyme-linked immunosorbent assays. IgG and IgA antibody responses to each antigen were observed in all age groups. Serum concentrations of IgG and IgA antibody responses to PspA and PdB (a recombinant toxoid derivative of pneumolysin), but not to PsaA, increased significantly with age (P < 0.001). No decline was observed in the sera of the elderly. Anti-protein IgG concentrations were only weakly correlated (0.30 < r < 0.56; P < 0.0001), as were IgA concentrations (0.24 < r < 0.54; P < 0.0001).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.